V asopressin I nitiation as a S econd-Line Vaso P ressor in Early S eptic S hock (VISPSS)

J Intensive Care Med. 2024 Apr;39(4):306-312. doi: 10.1177/08850666231201364. Epub 2023 Sep 16.

Abstract

Background: Vasopressin is recommended as a second-line vasoactive agent for the management of septic shock; however, a paucity of data to guide its optimal use remains. The aim was to evaluate the effect of time-to vasopressin initiation and norepinephrine (NE) dose at vasopressin initiation on clinical outcomes in patients presenting with septic shock.

Methods: This was a multi-centered, retrospective, observational study conducted in patients with septic shock. Patients were divided into 2 groups: patients initiated on vasopressin when NE-equivalent dose (NEE) < 0.25 mcg/kg/min or ≥ 0.25 mcg/kg/min. The primary outcome was time-to-vasopressor discontinuation (hours). Secondary outcomes included 28-day in-hospital mortality, intensive care unit (ICU) length of stay (LOS), fluid balance after 72 hours, and the change in NEE at 12 hours.

Results: A total of 302 patients were included in this study. After propensity-score matching, 73 patients in each group were identified for analysis. There was no significant difference in the time-to-vasopressor discontinuation (hours) between the groups (88.8 [55-187.5] vs 86.7 [47-172]); p = 0.7815). Fluid balance (mL) at 72 hours was significantly lower when vasopressin was initiated at NEE < 0.25 mcg/kg/min (1769 [71-7287] vs 5762 [1463-8813]; p = 0.0077). A multivariable linear regression showed shorter time to shock resolution with earlier vasopressin initiation, defined as within 4 hours (p < 0.05).

Conclusion: In this propensity-score matched cohort, vasopressin initiation at NEE < 0.25 mcg/kg/min was not associated with shorter vasopressor duration. There was a lower fluid balance at 72 hours when vasopressin was initiated at lower NE doses.

Keywords: septic shock; vasopressin; vasopressor agents.

Publication types

  • Observational Study
  • Multicenter Study

MeSH terms

  • Humans
  • Norepinephrine / adverse effects
  • Retrospective Studies
  • Shock, Septic* / drug therapy
  • Vasoconstrictor Agents / therapeutic use
  • Vasopressins / adverse effects

Substances

  • Vasoconstrictor Agents
  • Vasopressins
  • Norepinephrine